Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma

Centre Leon Berard112 enrolled

Overview

This is a multicenter prospective study:2 independant cohorts of patients with OMS grade II glioma will be followed during 5 years. * cohort A: patients in first-line treatment (surgery, radiotherapy or chemotherapy) * cohort B: patients with disease simple monitoring. The primary endpoint is to evaluate the impact of tumor and treatments on neurocognitive functions and quality of life, using validate and standard tests.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

112

Conditions

OMS Grade II Glioma

Interventions

neurocognitive testsBEHAVIORAL

* inclusion * 1 year * 3 years * 5 years

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * OMS grade II glioma * signed informed consent * age \>=18 * IK \>=80% * ability to read, write and undertand French Exclusion Criteria: * glioma localized to brainstem * other neurologic or psychiatric disease * history of other malignancies, other than curatively treated in-situ carcinoma of the cervix or basal cell carcinoma of the skin, or any other curatively treated cancer with no sign of recurrence within 5 years prior to randomization * neuroleptic concomitant treatment * pregnant or lactating women

Locations (21)

CH Amiens-Picardie

Amiens, France

Institut de Cancérologie de l'Ouest

Angers, France

Outcomes

Primary Outcomes

MoCA test

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.